<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37675163</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1844-3117</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of medicine and life</Title><ISOAbbreviation>J Med Life</ISOAbbreviation></Journal><ArticleTitle>COVID-19 in patients with rheumatological diseases in the Eastern Province of Saudi Arabia.</ArticleTitle><Pagination><StartPage>873</StartPage><EndPage>882</EndPage><MedlinePgn>873-882</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.25122/jml-2023-0037</ELocationID><Abstract><AbstractText>The severity of the 2019 coronavirus disease (COVID-19) and its effects remain unpredictable. Certain factors, such as obesity, hypertension, and type 2 diabetes mellitus, may increase the severity of the disease. Rheumatology experts suggest that patients with active autoimmune conditions and controlled autoimmune diseases on immunosuppressive therapy may be at higher risk of developing severe COVID-19. In this retrospective observational study, we aimed to examine the patterns of COVID-19 in patients with underlying rheumatological diseases and their association with disease severity and hospital outcomes. A total of 34 patients with underlying rheumatological diseases who tested positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by polymerase chain reaction (PCR) were included between March 2020 and April 2021 at King Fahd Hospital of the University. The study population consisted of 76.47% female and 23.53% male patients, with a mean age ranging from 20 to 40 years. Female gender (p=0.0001) and younger age (p=0.004) were associated with milder disease. The most frequent rheumatological disease was systemic lupus erythematosus (SLE) (38.24%), which was associated with a milder infection (p=0.045). Patients treated with mycophenolate mofetil (MMF) had a milder disease course (p=0.0037). Hypertension was significantly associated with severe COVID-19 disease (p=0.037). There was no significant relationship between SLE and the need for ICU admission. Patients on hydroxychloroquine and MMF tended to develop milder disease, and there was no association between the severity of the infection and the treatment with steroids.</AbstractText><CopyrightInformation>&#xa9;2023 JOURNAL of MEDICINE and LIFE.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alqatari</LastName><ForeName>Safi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nemer</LastName><ForeName>Ameera</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasan</LastName><ForeName>Manal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bukhari</LastName><ForeName>Raed</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Argan</LastName><ForeName>Reem</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Khafaji</LastName><ForeName>Dania</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alwaheed</LastName><ForeName>Abrar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alzaki</LastName><ForeName>Alaa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Wazza</LastName><ForeName>Marwan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Warthan</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Saeed</LastName><ForeName>Abir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albeladi</LastName><ForeName>Feda</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeer</LastName><ForeName>Hashim</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AlSulaiman</LastName><ForeName>Reem</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abu Quren</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, King Fahd Hospital, Imam Abdulrahman Bin Faisal University, Khobar, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Romania</Country><MedlineTA>J Med Life</MedlineTA><NlmUniqueID>101477617</NlmUniqueID><ISSNLinking>1844-122X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012529" MajorTopicYN="N" Type="Geographic">Saudi Arabia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE2: Angiotensin-converting enzyme 2</Keyword><Keyword MajorTopicYN="N">ANA: Antinuclear antibody</Keyword><Keyword MajorTopicYN="N">AOR: Adjusted odds ratio</Keyword><Keyword MajorTopicYN="N">ARDS: Acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">AT2: Type 2 alveolar cells</Keyword><Keyword MajorTopicYN="N">AZA: Azathioprine</Keyword><Keyword MajorTopicYN="N">BMI: Body mass index</Keyword><Keyword MajorTopicYN="N">CI: Confidence intervals</Keyword><Keyword MajorTopicYN="N">CK: Creatine kinase</Keyword><Keyword MajorTopicYN="N">CKD: Chronic kidney disease</Keyword><Keyword MajorTopicYN="N">COPD: Chronic obstructive pulmonary disease</Keyword><Keyword MajorTopicYN="N">COVID-19 infection</Keyword><Keyword MajorTopicYN="N">COVID-19: Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">CRP: C-reactive protein</Keyword><Keyword MajorTopicYN="N">CT: Computed tomography scan</Keyword><Keyword MajorTopicYN="N">CTD: Connective tissue disease</Keyword><Keyword MajorTopicYN="N">DM: Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">DMARDs: Disease-modifying antirheumatic drugs</Keyword><Keyword MajorTopicYN="N">ESR: Erythrocyte sedimentation rate</Keyword><Keyword MajorTopicYN="N">GI: Gastrointestinal</Keyword><Keyword MajorTopicYN="N">GPA: Granulomatosis with polyangiitis</Keyword><Keyword MajorTopicYN="N">HCQ: Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">ICU: Intensive Care Unit</Keyword><Keyword MajorTopicYN="N">IFN: Interferon</Keyword><Keyword MajorTopicYN="N">IL: Interleukin</Keyword><Keyword MajorTopicYN="N">ILD: Interstitial lung disease</Keyword><Keyword MajorTopicYN="N">IQR: Interquartile range</Keyword><Keyword MajorTopicYN="N">LDH: Lactate dehydrogenase</Keyword><Keyword MajorTopicYN="N">LOH: Length of hospitalization</Keyword><Keyword MajorTopicYN="N">MMF: Mycophenolate mofetil</Keyword><Keyword MajorTopicYN="N">MTX: Methotrexate</Keyword><Keyword MajorTopicYN="N">ORs: Odds ratios</Keyword><Keyword MajorTopicYN="N">PAN: Polyarteritis nodosa</Keyword><Keyword MajorTopicYN="N">PsA: Psoriatic arthritis</Keyword><Keyword MajorTopicYN="N">RA: Rheumatoid arthritis</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2</Keyword><Keyword MajorTopicYN="N">SD: Standard deviations</Keyword><Keyword MajorTopicYN="N">SLE: Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">SLEDAI: Systemic Lupus Erythematosus Disease Activity Index</Keyword><Keyword MajorTopicYN="N">SpO2: Oxygen saturation</Keyword><Keyword MajorTopicYN="N">TNF inhibitor: Tumor necrosis factor inhibitor</Keyword><Keyword MajorTopicYN="N">WHO: World Health Organization</Keyword><Keyword MajorTopicYN="N">disease outcome</Keyword><Keyword MajorTopicYN="N">disease severity</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">rheumatological disease</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37675163</ArticleId><ArticleId IdType="pmc">PMC10478665</ArticleId><ArticleId IdType="doi">10.25122/jml-2023-0037</ArticleId><ArticleId IdType="pii">JMedLife-16-873</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Favalli E, Ingegnoli F, De Lucia O, Cincinelli G, et al. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev. 2020;19(5):102523. doi: 10.1016/j.autrev.2020.102523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102523</ArticleId><ArticleId IdType="pmc">PMC7102591</ArticleId><ArticleId IdType="pubmed">32205186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou&#xe9;draogo D, Tiendr&#xe9;b&#xe9;ogo W, Kabor&#xe9; F, Ntsiba H. COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments. Clin Rheumatol. 2020;39(7):2069&#x2013;2075. doi: 10.1007/s10067-020-05176-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05176-8</ArticleId><ArticleId IdType="pmc">PMC7256179</ArticleId><ArticleId IdType="pubmed">32472461</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu C, Ko C, Wang J, Hsu T, Lin C. Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study. Arthritis Res Ther. 2019;21(1):211. doi: 10.1186/s13075-019-1925-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1925-7</ArticleId><ArticleId IdType="pmc">PMC6790041</ArticleId><ArticleId IdType="pubmed">31604447</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye C, Cai S, Shen G, Guan H, et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis. 2020;79(8):1007&#x2013;1013. doi: 10.1136/annrheumdis-2020-217627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217627</ArticleId><ArticleId IdType="pmc">PMC7295865</ArticleId><ArticleId IdType="pubmed">32444415</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, Danda D, Kavadichanda C, Das S, et al. Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. Rheumatol Int. 2020;40(10):1539&#x2013;1554. doi: 10.1007/s00296-020-04644-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04644-8</ArticleId><ArticleId IdType="pmc">PMC7360125</ArticleId><ArticleId IdType="pubmed">32666137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastritis E, Kitas G, Vassilopoulos D, Giannopoulos G, et al. Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatol Int. 2020;40(9):1353&#x2013;1360. doi: 10.1007/s00296-020-04633-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04633-x</ArticleId><ArticleId IdType="pmc">PMC7353833</ArticleId><ArticleId IdType="pubmed">32654078</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharmeen S, Elghawy A, Zarlasht F, Yao Q. COVID-19 in rheumatic disease patients on immunosuppressive agents. Semin Arthritis Rheum. 2020;50(4):680&#x2013;686. doi: 10.1016/j.semarthrit.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7245236</ArticleId><ArticleId IdType="pubmed">32512263</ArticleId></ArticleIdList></Reference><Reference><Citation>Nu&#xf1;o L, Novella Navarro M, Bonilla G, et al. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis. 2020;79(12):1659&#x2013;1661. doi: 10.1136/annrheumdis-2020-218641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218641</ArticleId><ArticleId IdType="pmc">PMC7677491</ArticleId><ArticleId IdType="pubmed">32606046</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Moiseev S, Avdeev S, Brovko M, Yavorovskiy A, et al. Rheumatic diseases in intensive care unit patients with COVID-19. Ann Rheum Dis. 2020;80(2):e16&#x2013;e16. doi: 10.1136/annrheumdis-2020-218208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218208</ArticleId><ArticleId IdType="pubmed">32434823</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Chen Z, Wang Y, Han L, et al. Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study. Ann Rheum Dis. 2020;79(9):1163&#x2013;1169. doi: 10.1136/annrheumdis-2020-217871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pmc">PMC7316114</ArticleId><ArticleId IdType="pubmed">32546598</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Silva K, Serling-Boyd N, Wallwork R, Hsu T, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US &#x2018;hot spot&#x2019;. Ann Rheum Dis. 2020;79(9):1156&#x2013;1162. doi: 10.1136/annrheumdis-2020-217888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217888</ArticleId><ArticleId IdType="pmc">PMC7456555</ArticleId><ArticleId IdType="pubmed">32457048</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques C, Pinheiro M, Reis Neto E, et al. COVID-19 in patients with rheumatic diseases: what is the real mortality risk? Ann Rheum Dis. 2020 doi: 10.1136/annrheumdis-2020-218388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218388</ArticleId><ArticleId IdType="pubmed">32660978</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzahrani Z, Alghamdi K, Almaqati A. Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases. Rheumatol Int. 2021;41(6):1097&#x2013;1103. doi: 10.1007/s00296-021-04745-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04745-0</ArticleId><ArticleId IdType="pmc">PMC8046898</ArticleId><ArticleId IdType="pubmed">33856543</ArticleId></ArticleIdList></Reference><Reference><Citation>Tharwat S, Zohdy Mohamed S, Kamal Nassar M. Challenges of Egyptian patients with systemic lupus erythematosus during the COVID-19 pandemic. Reumatologia. 2021;59(4):237&#x2013;243. doi: 10.5114/reum.2021.109165.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/reum.2021.109165</ArticleId><ArticleId IdType="pmc">PMC8436789</ArticleId><ArticleId IdType="pubmed">34538954</ArticleId></ArticleIdList></Reference><Reference><Citation>Abualfadl E, Ismail F, Shereef R, Hassan E, et al. Impact of COVID-19 pandemic on rheumatoid arthritis from a Multi-Centre patient-reported questionnaire survey: influence of gender, rural&#x2013;urban gap and north&#x2013;south gradient. Rheumatol Int. 2021;41(2):345&#x2013;353. doi: 10.1007/s00296-020-04679-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04679-x</ArticleId><ArticleId IdType="pmc">PMC7603433</ArticleId><ArticleId IdType="pubmed">33130920</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassen L, Almaghlouth I, Hassen I, Daghestani M, et al. Impact of COVID-19 outbreak on rheumatic patients&#x2019; perceptions and behaviors: A cross-sectional study. Int J Rheum Dis. 2020;23(11):1541&#x2013;1549. doi: 10.1111/1756-185X.13979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13979</ArticleId><ArticleId IdType="pubmed">32940963</ArticleId></ArticleIdList></Reference><Reference><Citation>Freites Nu&#xf1;ez D, Leon L, Mucientes A, Rodriguez-Rodriguez L, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(11):1393&#x2013;1399. doi: 10.1136/annrheumdis-2020-218479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218479</ArticleId><ArticleId IdType="pubmed">32769150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez-de-Arellano A, Guti&#xe9;rrez-Franco J, Sierra-Diaz E, Pereira-Su&#xe1;rez A. The role of estradiol in the immune response against COVID-19. Hormones. 2021;20(4):657&#x2013;667. doi: 10.1007/s42000-020-00263-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42000-020-00263-x</ArticleId><ArticleId IdType="pmc">PMC8210971</ArticleId><ArticleId IdType="pubmed">34142358</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J, Bai P, He W, Wu F, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health. 2020;8:152. doi: 10.3389/fpubh.2020.00352.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.00352</ArticleId><ArticleId IdType="pmc">PMC7201103</ArticleId><ArticleId IdType="pubmed">32411652</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahidy F, Pan A, Ahnstedt H, Munshi Y, et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. PLoS One. 2021;16(1):e0245556. doi: 10.1371/journal.pone.0245556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0245556</ArticleId><ArticleId IdType="pmc">PMC7806140</ArticleId><ArticleId IdType="pubmed">33439908</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasseli R, Mueller-Ladner U, Hoyer B, Krause A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7(1):e001464. doi: 10.1136/rmdopen-2020-001464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001464</ArticleId><ArticleId IdType="pmc">PMC7823432</ArticleId><ArticleId IdType="pubmed">33479021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng W, Tipih T, Makoah N, Vermeulen J, et al. Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis. mBio. 2021;12(1):e03647&#x2013;20. doi: 10.1128/mBio.03647-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.03647-20</ArticleId><ArticleId IdType="pmc">PMC7885108</ArticleId><ArticleId IdType="pubmed">33563817</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Ruiz R, Paredes J, Niewold T. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res. 2021;232:13&#x2013;36. doi: 10.1016/j.trsl.2021.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2021.03.004</ArticleId><ArticleId IdType="pmc">PMC7749645</ArticleId><ArticleId IdType="pubmed">33352298</ArticleId></ArticleIdList></Reference><Reference><Citation>Grainger R, Machado P, Robinson P. Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. Best Pract Res Clin Rheumatol. 2021;35(1):101657. doi: 10.1016/j.berh.2021.101657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2021.101657</ArticleId><ArticleId IdType="pmc">PMC7756169</ArticleId><ArticleId IdType="pubmed">33468418</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  COVID-19 clinical management: living guidance, 25 January 2021. World Health Organization. 2021.  Available from:  https://apps.who.int/iris/handle/10665/338882.</Citation></Reference><Reference><Citation>Roumier M, Paule R, Groh M, Vallee A, Ackermann F. Interleukin-6 blockade for severe COVID-19. medRxiv. 2020 doi: 10.1101/2020.03.20.20038961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.20.20038961</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859&#x2013;866. doi: 10.1136/annrheumdis-2020-217871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Arlettaz R, Fitting C, Thurneysen S, Spath P, et al. Bilateral pulmonary thrombosis in COVID-19 pneumonia. Clin Microbiol Infect. 2020;26(11):1561&#x2013;1563. doi: 10.1016/j.cmi.2020.07.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahan S, Segal G, Katz I, Hellou T, et al. Ferritin as a Marker of Severity in COVID-19 Patients: A Fatal Correlation. Isr Med Assoc J. 2020;22(8):494&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">33236582</ArticleId></ArticleIdList></Reference><Reference><Citation>Bui L, Winters N, Chung M, Joseph C, et al. Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity. Nat Commun. 2021;12(1):6023. doi: 10.1038/s41467-021-26384-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26384-4</ArticleId><ArticleId IdType="pmc">PMC8280215</ArticleId><ArticleId IdType="pubmed">34262047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Choi H, Yang B, Lee S, et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J. 2021;58(6):2004125. doi: 10.1183/13993003.04125-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.04125-2020</ArticleId><ArticleId IdType="pmc">PMC8061231</ArticleId><ArticleId IdType="pubmed">33888524</ArticleId></ArticleIdList></Reference><Reference><Citation>Juge P, Hachulla E, Richez C, Drumez E, et al. Impact of a pre-existing interstitial lung disease on severity of COVID-19 in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(1):897. doi: 10.1136/annrheumdis-2021-eular.4066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-eular.4066</ArticleId></ArticleIdList></Reference><Reference><Citation>Hojyo S, Uchida M, Tanaka K, Hasebe R, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40(1):37. doi: 10.1186/s41232-020-00146-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-020-00146-3</ArticleId><ArticleId IdType="pmc">PMC7527296</ArticleId><ArticleId IdType="pubmed">33014208</ArticleId></ArticleIdList></Reference><Reference><Citation>Avouac J, Air&#xf3; P, Carlier N, Matucci-Cerinic M, Allanore Y. Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. Ann Rheum Dis. 2020;80(3):e37. doi: 10.1136/annrheumdis-2020-217864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217864</ArticleId><ArticleId IdType="pubmed">32503849</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Tsukune Y, Watanabe N, Sugimoto K, et al. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(11):774&#x2013;776. doi: 10.1016/j.clml.2020.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7442568</ArticleId><ArticleId IdType="pubmed">32933879</ArticleId></ArticleIdList></Reference><Reference><Citation>Loarce-Martos J, Garc&#xed;a-Fern&#xe1;ndez A, L&#xf3;pez-Guti&#xe9;rrez F, Garc&#xed;a-Garc&#xed;a V, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40(12):2015&#x2013;2021. doi: 10.1007/s00296-020-04699-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04699-x</ArticleId><ArticleId IdType="pmc">PMC7499013</ArticleId><ArticleId IdType="pubmed">32945944</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>